18 nov: Scor 400.000 på din pension
19 nov: Den vildeste Porsche
19-11-2010 10:37:27

AstraZeneca confirms eyeing Astra Tech spin-off

Relateret indhold

LONDON (Reuters) - AstraZeneca (Astrazeneca PLC ORD SHS $0.25) confirmed on Friday it was considering spinning off its Astra Tech dental implants and medical devices business and had hired JP Morgan Chase (JPMorgan Chase & Co) to help with a strategic review of the unit.

A source familiar with the situation said earlier this week that the Anglo-Swedish drugmaker was looking to sell the non-core Swedish-based business for some $2 billion (1.2 billion pounds) after hiring the bank as adviser.

"AstraZeneca continues to evaluate all alternatives for value maximisation from this business and any final decision will only be made when the results of the review have concluded," the company said in a brief statement.

A company spokeswoman confirmed that a sale of the operation was one option. She declined to comment on the timing of any decision.

The expected sale of Astra Tech highlights AstraZeneca's current focus on boosting returns as the group heads into a wave of patent expiries on some of its biggest-selling medicines.

In contrast to some of its rivals -- such as GlaxoSmithKline (GlaxoSmithKline PLC), Novartis and Sanofi-Aventis -- AstraZeneca has stayed focussed on its core pharmaceuticals business rather than seeking diversification.

Shares in the company were barely changed by 9:30 a.m., down 0.3 percent at 3053.5 pence, in line with a flat Stoxx 600 European healthcare sector index .

The Astra Tech business could be of interest to U.S. companies such as privately held Biomet, Medtronic (Medtronic Inc), 3M (3M Co), Danaher (Danaher Corp) and Dentsply International (Dentsply International Inc), as well as private equity firms, according to industry analysts.

Companies operating in the sector in Europe include Swiss dental implant firms Nobel Biocare and Straumann .

Astra Tech, best known for dental implants, also sells urological catheters, breathing aids and blood management systems used in surgery. It has 2,200 employees worldwide and produced revenue in 2009 of $506 million, AstraZeneca said.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo/ABM: Løfter kursmål med 13 pct. inden regnskab - NY

26-01-2015 14:25:37
Alm. Brand Markets ser frem mod årsregnskabet fra medicinalselskabet Novo Nordisk med positive forventninger og løfter sit kursmål for aktien til 340 kr. fra ti..

Aktier/middag: C20 genfinder rekordrytmen med Vestas i spidsen

26-01-2015 11:29:30
Vestas og resten af de danske eliteaktier har vendt morgentimernes nedadvendte mundvige opad og lagt sig tilbage på rekordkurs.C20 Cap-indekset ligger sidst på ..

Aktier/tendens: Græsk valg sætter stopper for rekordjagt

26-01-2015 08:12:36
Efter fem rekorder i træk til C20 Cap sidste uge er der lagt op til mere pessimistiske investorer i mandagens handel.De europæiske aktiemarkeder indikeres at åb..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo/ABM: Løfter kursmål med 13 pct. inden regnskab - NY
2
Bang & Olufsen stiger på salgsrygte
3
Aktier/middag: C20 genfinder rekordrytmen med Vestas i spidsen
4
Genmab/Danske: Kursmålet øges med en tredjedel
5
Aktier/tendens: Græsk valg sætter stopper for rekordjagt

Relaterede aktiekurser

Medtronic Inc 75,59 -1,8% Fald i aktiekurs
JPMorgan Chase & Co 56,77 0,2% Stigning i aktiekurs
GlaxoSmithKline PLC 1.498,50 -0,1% Fald i aktiekurs
3M Co 164,24 0,1% Stigning i aktiekurs
Danaher Corp 83,66 -0,6% Fald i aktiekurs
Astrazeneca PLC ORD SHS .. 4.700,00 -0,7% Fald i aktiekurs
Dentsply International I.. 50,75 -0,3% Fald i aktiekurs
Straumann N 205,90 2,0% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. januar 2015 23:28:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150121.1 - EUROWEB7 - 2015-01-26 23:28:50 - 2015-01-26 23:28:50 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x